Stratos Wealth Partners’s Protalix BioTherapeutics PLX Stock Holding History

Stratos Wealth Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.08M	Hold	500,000	–	–	0.01%	764
2025 Q4	$900K	Hold	500,000	–	–	0.01%	811
2025 Q3	$1.11M	Buy	500,000 +150,000	+43%	+$244K	0.01%	709
2025 Q2	$518K	Buy	350,000 +3,600	+1%	+$7.37K	0.01%	915
2025 Q1	$887K	Buy	346,400 +76,400	+28%	+$182K	0.01%	708
2024 Q4	$508K	Hold	270,000	–	–	0.01%	930
2024 Q3	$275K	Buy	+270,000	New	+$284K	﹤0.01%	1189

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stratos Wealth Partners's PLX Position: Q1 2026 in Review

Stratos Wealth Partners held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 500,000 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #764.

Stratos Wealth Partners first reported a position in PLX in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.11M in Q3 2025. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Stratos Wealth Partners held 500,000 shares of Protalix BioTherapeutics worth $1.08M as of Q1 2026.
Stratos Wealth Partners left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up 0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #764 holding.
Stratos Wealth Partners first reported a position in Protalix BioTherapeutics in Q3 2024 and has held it in 7 quarters since.
Stratos Wealth Partners's Protalix BioTherapeutics position peaked at $1.11M in Q3 2025.
100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.